Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Jean Pierre Gotteland"'
Autor:
Jörg Täubel, Ulrike Lorch, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Dilshat Djumanov, Georg Ferber, Line Marchand, Jean-Pierre Gotteland, Oliver Pohl
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Nolasiban is an orally active oxytocin receptor antagonist being developed to increase the efficiency of assisted reproductive technologies. This study evaluated the pharmacokinetics, pharmacodynamics, and cardiac safety of nolasiban in 45 h
Externí odkaz:
https://doaj.org/article/941c758ff82c46db9ab0bd9fda565dc9
Publikováno v:
British Journal of Clinical Pharmacology. 88:2359-2371
To identify linzagolix doses, an oral GnRH receptor antagonist, that effectively lower oestradiol (E2) to relieve endometriosis-related pelvic pain without compromising bone health.Integrated statistical, pharmacokinetic-pharmacodynamic and systems p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66daa4396873d096c432fdf462df7d62
https://doi.org/10.1111/bcp.15171
https://doi.org/10.1111/bcp.15171
Autor:
Line Marchand, Georg Ferber, Jean-Pierre Gotteland, Oliver Pohl, Dorothée Camilleri, Anne Freier, Dilshat Djumanov, Christopher S. Spencer, Ulrike Lorch, Jorg Taubel
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Scientific Reports
Scientific Reports
Nolasiban is an orally active oxytocin receptor antagonist being developed to increase the efficiency of assisted reproductive technologies. This study evaluated the pharmacokinetics, pharmacodynamics, and cardiac safety of nolasiban in 45 healthy wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e1e0c6bc1df476b79c7c40414930d3c
https://doaj.org/article/941c758ff82c46db9ab0bd9fda565dc9
https://doaj.org/article/941c758ff82c46db9ab0bd9fda565dc9
Autor:
Jacques Donnez, Hugh S Taylor, Elizabeth A Stewart, Linda Bradley, Erica Marsh, David Archer, Ayman Al-Hendy, Felice Petraglia, Nelson Watts, Jean-Pierre Gotteland, Elke Bestel, Paul Terrill, Ernest Loumaye, Andrew Humberstone, Elizabeth Garner
Publikováno v:
Lancet (London, England). 400(10356)
Uterine fibroids are common non-cancerous neoplasm that cause heavy menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone receptor antagonist taken once per day that dose-dependently suppresses gonadal steroids and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::208512ce2299b2dc15d2a6afd85f46ac
https://pubmed.ncbi.nlm.nih.gov/36116467
https://pubmed.ncbi.nlm.nih.gov/36116467
Autor:
Jacques Donnez, Veronique Lecomte, Jean-Pierre Gotteland, Hugh S. Taylor, Mark D. Akin, Krzysztof Wilk, Tatyana F. Tatarchuk, Elke Bestel, Robert N. Taylor
Publikováno v:
Fertility and Sterility. 114:44-55
Objective To study the effect of a new investigational oral gonadotropin-releasing hormone antagonist, linzagolix, on endometriosis-associated pain (EAP). Design A multinational, parallel group, randomized, placebo-controlled, double-blind, dose-rang
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::531a6e21c7f2d90182fe114880f59357
https://doi.org/10.1016/j.fertnstert.2020.02.114
https://doi.org/10.1016/j.fertnstert.2020.02.114
Autor:
Shari Mackens, Jean-Pierre Gotteland, Christophe Blockeel, Oliver Pohl, Ulrike Lorch, Line Marchand, Piotr Pierzynski
RESEARCH QUESTION: What are the effects of the oxytocin receptor (OTR) antagonist nolasiban on uterine contractions, endometrial perfusion and endometrial mRNA expression? DESIGN: Randomized, double-blind, parallel-group, mechanism-of-action study wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534b26df813340c47619ecda51a5f11c
https://hdl.handle.net/20.500.14017/a0ba457c-ce98-4811-a605-7429478e0ce6
https://hdl.handle.net/20.500.14017/a0ba457c-ce98-4811-a605-7429478e0ce6
Publikováno v:
Br J Clin Pharmacol
AIMS: To investigate presence or absence of clinically relevant drug interactions (pharmacokinetic and safety/tolerability) of OBE022 with standard‐of‐care medicines for preterm labour, enabling coadministration and further clinical development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a77ff15e608e6638b5cfe67836a49bd4
https://doi.org/10.1111/bcp.13925
https://doi.org/10.1111/bcp.13925
Publikováno v:
British Journal of Clinical Pharmacology. 84:1839-1855
Aims Preterm birth remains a significant risk for later disability. The selective inhibition of the prostaglandin F2α receptor has significant advantages for a tocolytic. The prodrug OBE022 and its metabolite OBE002 are novel prostaglandin F2α rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cd365a57a2d816308271289061c1780
https://doi.org/10.1111/bcp.13622
https://doi.org/10.1111/bcp.13622
Autor:
Sung Hye Kim, Phillip R. Bennett, Philippe Guillaume, Frédéric Gervais, André Chollet, Lucia Riaposova, François Spézia, Murielle Méen, Philippe Lluel, Jean-Pierre Gotteland, Frédérique Lemaux, Oliver Pohl, Vasso Terzidou
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 366:349-364
Preterm birth is the major challenge in obstetrics, affecting ∼10% of pregnancies. Pan-prostaglandin synthesis inhibitors [nonsteroidal anti-inflammatory drugs (NSAIDs)] prevent preterm labor and prolong pregnancy but raise concerns about fetal ren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4a7726e8255b278cbee082ebffa5c28
https://doi.org/10.1124/jpet.118.247668
https://doi.org/10.1124/jpet.118.247668
Autor:
Simon Coates, Paul Foley, Ulrike Lorch, Jean-Pierre Gotteland, Oliver Pohl, Sara Fernandes, Georg Ferber, Jorg Taubel
Publikováno v:
Clinical Pharmacology in Drug Development
OBE022, a new orally active prostaglandin F2α receptor antagonist (OBE022) with myometrial selectivity is being developed to reduce uterine contractions during preterm labor. This first‐in‐human study evaluated the effect of OBE022 following mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8819adddbb537619b243ef42d349bda3
http://europepmc.org/articles/PMC6221050
http://europepmc.org/articles/PMC6221050